BEIGENE LTD-ADR (BGNE)
US07725L1026 - ADR
Overall BGNE gets a fundamental rating of 3 out of 10. We evaluated BGNE against 588 industry peers in the Biotechnology industry. The financial health of BGNE is average, but there are quite some concerns on its profitability. BGNE shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year BGNE has reported negative net income.
In the past year BGNE has reported a negative cash flow from operations.
BGNE had negative earnings in each of the past 5 years.
BGNE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BGNE has a better Return On Assets (-17.63%) than 84.59% of its industry peers.
BGNE has a Return On Equity of -25.95%. This is amongst the best in the industry. BGNE outperforms 83.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.63% | ||
| ROE | -25.95% | ||
| ROIC | N/A |
ROA(3y)-26.55%
ROA(5y)-34.38%
ROE(3y)-38.11%
ROE(5y)-51.15%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BGNE has a better Gross Margin (84.31%) than 89.55% of its industry peers.
In the last couple of years the Gross Margin of BGNE has declined.
The Profit Margin and Operating Margin are not available for BGNE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-3.94%
2. Health
2.1 Basic Checks
BGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for BGNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BGNE has an Altman-Z score of 3.41. This indicates that BGNE is financially healthy and has little risk of bankruptcy at the moment.
BGNE has a Altman-Z score of 3.41. This is in the better half of the industry: BGNE outperforms 77.05% of its industry peers.
BGNE has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.14, BGNE is doing worse than 65.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.41 |
ROIC/WACCN/A
WACC9.1%
2.3 Liquidity
A Current Ratio of 3.12 indicates that BGNE has no problem at all paying its short term obligations.
The Current ratio of BGNE (3.12) is worse than 65.07% of its industry peers.
BGNE has a Quick Ratio of 2.88. This indicates that BGNE is financially healthy and has no problem in meeting its short term obligations.
BGNE has a worse Quick ratio (2.88) than 65.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
BGNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.86%, which is quite impressive.
The Revenue has grown by 89.19% in the past year. This is a very strong growth!
The Revenue has been growing by 109.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)53.86%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q138.68%
Revenue 1Y (TTM)89.19%
Revenue growth 3Y47.95%
Revenue growth 5Y109.26%
Revenue growth Q2Q111.55%
3.2 Future
BGNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.77% yearly.
BGNE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.41% yearly.
EPS Next Y48.75%
EPS Next 2Y24.46%
EPS Next 3Y20.27%
EPS Next 5Y34.77%
Revenue Next Year76.74%
Revenue Next 2Y49.34%
Revenue Next 3Y43.31%
Revenue Next 5Y35.41%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGNE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BGNE's earnings are expected to grow with 20.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.46%
EPS Next 3Y20.27%
5. Dividend
5.1 Amount
No dividends for BGNE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEIGENE LTD-ADR
NASDAQ:BGNE (4/25/2024, 5:49:03 PM)
After market: 143.64 -4.92 (-3.31%)148.56
+4.44 (+3.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap15.52B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.63% | ||
| ROE | -25.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.31% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)53.86%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y48.75%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)89.19%
Revenue growth 3Y47.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y